Search research articles
Contact Us
Filters
Showing results (1-10 of 76) with videos related to
Page
of 8
Sort By:
The Journal of Urology
|
September 12, 2022
Editorial Comment
Ted A Skolarus, Russell Z Szmulewitz
Journal of Clinical Pharmacology
|
April 24, 2014
Vemurafenib oral bioavailability: an insoluble problem
Russell Z Szmulewitz, Mark J Ratain
Nature Clinical Practice. Oncology
|
June 28, 2007
Sunitinib--a new standard of care for metastatic renal cell carcinoma
Walter M Stadler, Russell Z Szmulewitz
Science Translational Medicine
|
September 18, 2015
Targeting the glucocorticoid receptor in breast and prostate cancers
Jacob Kach, Suzanne D Conzen, Russell Z Szmulewitz
Indian Journal of Urology : IJU : Journal of the Urological Society of India
|
June 11, 2010
Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies
Gautam Jayram, Russell Z Szmulewitz, Scott E Eggener
The Prostate
|
September 2, 2014
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells
Steven Kregel, Russell Z Szmulewitz, Donald J Vander Griend
JAMA Oncology
|
March 4, 2021
The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check
Russell Z Szmulewitz, Walter M Stadler, Mark J Ratain
European Urology
|
September 4, 2012
A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer
Daniel M Geynisman, Russell Z Szmulewitz, Walter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 7, 2018
Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al
Russell Z Szmulewitz, Walter M Stadler, Mark J Ratain
European Urology
|
August 25, 2014
Corticosteroids and prostate cancer: friend or foe?
Daniel M Geynisman, Russell Z Szmulewitz, Elizabeth R Plimack
Page
of 8
Search research articles
Search
Showing results (1-10 of 76) with videos related to
Sort By:
Page
of 8
The Journal of Urology
|
September 12, 2022
Editorial Comment
Ted A Skolarus, Russell Z Szmulewitz
Journal of Clinical Pharmacology
|
April 24, 2014
Vemurafenib oral bioavailability: an insoluble problem
Russell Z Szmulewitz, Mark J Ratain
Nature Clinical Practice. Oncology
|
June 28, 2007
Sunitinib--a new standard of care for metastatic renal cell carcinoma
Walter M Stadler, Russell Z Szmulewitz
Science Translational Medicine
|
September 18, 2015
Targeting the glucocorticoid receptor in breast and prostate cancers
Jacob Kach, Suzanne D Conzen, Russell Z Szmulewitz
Indian Journal of Urology : IJU : Journal of the Urological Society of India
|
June 11, 2010
Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies
Gautam Jayram, Russell Z Szmulewitz, Scott E Eggener
The Prostate
|
September 2, 2014
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells
Steven Kregel, Russell Z Szmulewitz, Donald J Vander Griend
JAMA Oncology
|
March 4, 2021
The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check
Russell Z Szmulewitz, Walter M Stadler, Mark J Ratain
European Urology
|
September 4, 2012
A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer
Daniel M Geynisman, Russell Z Szmulewitz, Walter M Stadler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 7, 2018
Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al
Russell Z Szmulewitz, Walter M Stadler, Mark J Ratain
European Urology
|
August 25, 2014
Corticosteroids and prostate cancer: friend or foe?
Daniel M Geynisman, Russell Z Szmulewitz, Elizabeth R Plimack
Page
of 8